Raymed Labs Ltd Board Meeting

2.5
(4.60%)
Jul 8, 2024|12:00:00 AM

Raymed Labs CORPORATE ACTIONS

24/07/2023calendar-icon
23/07/2024calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting24 May 202413 May 2024
RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 inter alia to consider and approve Audited Standalone Financial Results as per Regulation 33 of SEBI (LODR) Regulations 2015 for the quarter and year ended March 31 2024 Approval of Audited Standalone Financial Results for the quarter and year ended March 31, 2024 Outcome of Board Meeting Dated 24/05/2024 (As Per BSE Announcement Dated on 24/05/2024)
Board Meeting17 Apr 202417 Apr 2024
Outcome of Board Meeting pursuant to under Regulation 30 of SEBI (LODR) Regulations, 2015- change in Registered office of the Company within Local Limits
Board Meeting6 Feb 202425 Jan 2024
RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve Unaudited Standalone Financial Results for the Quarter ended 31st December 2023. Approval of Unaudited Stanalone Financial Result for the Quarter ended 31st December 2023 of Raymed Labs Limited (As Per BSE Announcement Dated on: 06/02/2024) Intimation under Regulation 30 of SEBI LODR Regulation , 2015 -Newspaper Publication (As Per BSE Announcement Dated on 07/02/2024)
Board Meeting15 Dec 202315 Dec 2023
Intimation under Regulation 30(5) of SEBI LODR Regulations 2015-Authorisation & Contact details of Key Managerial Personnel of the Company
Board Meeting4 Nov 202327 Oct 2023
RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve Unaudited Standalone Financial Results as per Regulation 33 of SEBI (LODR) Regulations 2015 for quarter and half year ended September 30 2023 together with the Limited Review Report. Un-audited Standalone Financial Results for the quarter and half year ended September 30, 2023 Outcome of Board Meeting for approval of Un-audited Financial Results for the Quarter and Half Year ended September 30, 2023 Outcome of Board Meeting dated 04/11/2023 (As Per BSE Announcement Dated on 04/11/2023)
Board Meeting2 Aug 202322 Jul 2023
RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve unaudited financial results for quarter ended June 30 2023 Approval of Unaudited Standalone Financial Results for the Quarter ended 30.06.2022 Outcome of Board Meeting held on 02.08.2023 Book Closure dated from Saturday, 26th Day of August 2023 to Friday, the 1st day of September, 2023(both days inclusive) (As Per BSE Announcement dated on 02.08.2023) Revised Unaudited Standalone Financial Results for quarter ended 30th June, 2023 (As Per BSE Announcement dated on 08.08.2023)

Raymed Labs: Related News

No record found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.